ScreenPoint Medical has signed a memorandum of understanding (MOU) with Volpara Health Technologies. Volpara will deliver ScreenPoint’s artificial intelligence (AI)-based products to customers as part of its expanding VolparaEnterprise AI cloud ecosystem. Together, the two companies expect to improve the clinical performance of mammography and drive the earlier detection of breast cancer. The partnership will leverage Volpara’s growing footprint in the breast imaging marketplace and will provide an opportunity for ScreenPoint to enter the U.S. market.

VigiLanz and Cincinnati Children’s Hospital Medical Center recently announced a collaboration that leverages Cincinnati Children’s research on pediatric nephrotoxic kidney injury and VigiLanz’s capabilities to commercialize a solution for acute kidney injury (AKI) in pediatric patients. Dubbed NINJA, or Nephrotoxic Injury Negated by Just-in-time Action, the solution enables real-time identification and monitoring of patients at risk for AKI due to exposure to nephrotoxic drugs.

Clinical diagnostics intelligence platform company MaxQ AI and Samsung NeuroLogica announced a distribution agreement to integrate MaxQ’s artificial intelligence (AI) software with Samsung NeuroLogica’s medical imaging hardware in the United States and European Union acute care marketplace. As part of this agreement, Samsung NeuroLogica will be able enhance its offerings with MaxQ’s Accipio Ix, part of MaxQ’s Accipio Insight intracranial hemorrhage platform, which supports acute care physicians by identifying patients with suspected intracranial hemorrhage, and prioritizing those patients using adult non-contrast head computed tomography (CT) imaging.

Vital, a Canon Group company, will highlight the latest additions to its enterprise imaging portfolio at the 2018 Radiological Society of North America (RSNA) annual meeting, Nov. 25-30 in Chicago. In 2018, the company is also celebrating its 30th anniversary.